Together, these findings demonstrate that BMAL1-HIF2α heterodimers promote the growth of ccRCC xenografts and are sensitive to disruption by the HIF2α antagonist PT2399 in vivo. Here, BMAL1 is linked to nonpapillary renal cell carcinoma.